A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
NCT04529122
Summary
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.
Eligibility
Inclusion Criteria: * Participant is an adult (according to the age of majority as defined by local regulations) * Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date) * Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results * Informed consent has been obtained from the participant or legally authorized representative, as per local regulations Exclusion Criteria: -Participant has a prior or current diagnosis of haematological malignancy
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT04529122